Abstract Aim-To carry
The cytoskeleton of 6 Whilst carcinomas usually express the cytokeratin profile of their tissue of origin,' 6 exceptions may occur. Tumours may either begin to express a novel cytokeratin or, alternatively, may cease to express cytokeratins which are normally present in their tissue of origin.7 Furthermore, changes in the profile of cytokeratin expression have been found with increasing tumour grade. These changes may also be caused by alterations in the epitope configuration of some cytokeratins.8
This study was carried out to determine whether cytokeratin expression can be used to distinguish malignant tumours of the breast from benign conditions. The value of cytokeratm expression in predicting patient prognosis was also studied, by seeking an association between the expression of different cytokeratins and tumour grade, in ductal carcinomas. The expression of cytokeratins in breast myoepithelium and in a group of unusual tumours is also described.
As routine tissue processing with formalin based fixatives results in denaturing of antigens, this study was performed on frozen section material. Although resulting in some loss in the quality of morphology, the use of frozen sections provides the optimal means for preserving immunoreactivity. Alcohol fixation and freeze drying followed by embedding the material in paraffin wax result in only mild antigenetic distortion and give good morphology. 3 1' 12 Methods Fresh specimens of breast tissue, including those from lumpectomies and mastectomies for malignant conditions and local excisions for benign breast disease, were transported on ice from the operating theatre to the histopathology laboratory. In most cases a previous fine needle aspiration biopsy had been performed and a diagnosis of benign or malignant breast disease had been established. On arrival in the laboratory, the resection margins were marked with indian ink. Impalpable lesions were fixed in 10% unbuffered formol saline before sectioning and were excluded from the study. All other specimens were sectioned at 1 cm intervals.
A small portion of tissue measuring 1 x 1 x 0-5 cm was excised and immediately The reaction pattern of the various antibodies with the myoepithelial cells surrounding areas of in situ ductal carcinoma and the benign breast diseases were compared using the Mann-Whitney U test. A p value of < 0-05 was considered significant. 
Results
Cytokeratins were detected in the luminal epithelium of the 19 fibroadenoma cases, the 19 cases of fibrocystic disease, the three phyllodes tumour cases, and in the tumour cells in the 68 cases infiltrating ductal, the seven cases of lobular, and the three cases of mucinous carcinoma (table 2 and The complete absence of simple cytokeratins in breast ductal and lobular carcinomas may be because these tumours may have arisen in those luminal epithelial cells of the terminal duct lobular units which did not express these proteins.20 That this represents a genuine absence of the cytokeratin, rather than masking of an epitopic site or the effect of fixation, is supported by studies in which several antibodies were used, reacting with more than one epitopic site on a given cytokeratin,722 and by the use of frozen sections, in which immunoreactivity is optimally preserved, as in the current series.
As cases in which all of the epithelial cells were negative for cytokeratins 7, 8, and 18 were limited to carcinomas, the use of these antibodies may provide a convenient means for distinguishing benign from malignant breast disease in some borderline cases. The cancer cells in two adenocarcinomas were completely negative for cytokeratin 19 and a statistically significant difference was found when cytokeratin 19 expression was compared in ductal carcinomas and benign breast I Figure 6 The myoepithelial cells also reacted to an antibody to actin. This antibody also reacts with the blood vessels in the adjacent stroma (frozen section x 240).
disease. However, as the luminal epithelium in one case of fibroadenoma was entirely nonreactive for this antibody, its value as a diagnostic discriminator is limited. Findings similar to those described in cases of benign breast disease were identified in the luminal epithelium in the two phyllodes tumours.
Three cytokeratin 14 positive tumours were observed in this series and in one case all of the tumour cells were positive. Gustersen et a125 and Wetzels et al'6 identified basement membrane components in the tumour cells in a proportion of such tumours, suggesting that they arose from the myoepithelial layer of the breast. However, cytokeratin 14 expression in the absence of other markers of myoepithelial differentiation has also been described in breast tumours. 26 Occasional luminal cells in the terminal duct lobular unit, which react with antibodies to cytokeratin 14, have been described by Nagle et al 27 and these cells may be the origin of some cytokeratin 14 positive tumours. Cytokeratin 14 expression may also represent a change in the cytokeratin profile with the acquisition of malignant char- acteristics. The acquisition of cytokeratin 14 expression has been described in tumours of the urinary bladder.8 The finding that both simple cytokeratins and cytokeratin 14 were co-expressed in three tumours in the present study and that none of them reacted to a specific antibody to actin would lend support to either of these latter hypotheses.
Reactions with the antibodies AE2 (cytokeratins 1, 2, 10, and 11), AE5 (cytokeratin 3), AE8 (cytokeratin 13), RSKE60 (cytokeratin 10), and 6B10 (cytokeratin 4) were identified in the luminal epithelium in occasional cases of benign breast disease and of invasive cancers. Of these, only cytokeratin 13 has been previously reported within breast epithehium.'6 Statistically significant differences in cytokeratin expression with increasing tumour grade did not occur with any of the antibodies studied. Therefore, the value of the cytokeratin profile in assessing tumour grade and prognosis in breast carcinoma appears to be limited.
The detection in myoepithelium of cytokeratins 7, 18, 19, and 14 with specific antibodies to these proteins reflects the results of previous studies. 15-182326-30 The reaction with myoepithelium of a number of antibodies which detect more than one cytokeratin reflects their ability to detect specific cytokeratins which are known to be expressed by these cells (Cam 5-2, cytokeratins 18 and 19; RCK102, cytokeratin 5; AE1, cytokeratin 14; AE3, cytokeratin 5; LP34, cytokeratin 18). Of these, cytokeratin 14 has been most extensively studied. Cytokeratin 14 expression has been localised to the myoepithelial cells in the normal breast, in cases of benign breast disease16182326-30 and in surrounding foci of in situ carcinoma.'62729 In this study and that of Dairkee et a126 a reaction to cytokeratin 14 in the myoepithelial cells was absent in some cases of benign disease. As in this series, Gottlieb et al30 found that a monoclonal antibody to cytokeratin 14 was a less sensitive means of detecting myoepithelial cells than the use of antiactin antibodies. This is the first study in which cytokeratins 1, 2, 10, or 11 (AE2), cytokeratin 3 (AE5), cytokeratin 10 (RSKE60), and cytokeratin 4 (6B 10) have been immunolocalised in myoepithelial cells. In contrast to our findings Nagle et al27 were unable to detect cytokeratin 13 in these cells using an alternative antibody (2D7). Neither we nor TaylorPapadimitriou24 or Guelstein et al3 were able to detect cytokeratin 8 in myoepithelial cells.
In conclusion, cytokeratins 7, 8 , and 18 were invariably expressed in benign breast disease and when absent, were reliable indicators of malignancy. Cytokeratin expression showed no statistically significant association with breast tumours of differing histological grade, but was of some value in outlining the myoepithelial layers surrounding foci of in situ carcinoma, enabling these lesions to be differentiated from invasive carcinomas. 
